Historically, survival rates for mesothelioma are measured in terms of one-year survival. However, more mesothelioma patients are beating the odds and living far beyond median survival rates thanks to advances in treatment.
Additionally, five-year survival for mesothelioma patients has steadily improved since 1999, according to the latest report from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program.
Long-term survivors attribute their success to a multidisciplinary approach to treatment from mesothelioma specialists, alternative medicine, clinical trials and nutritional changes.
Mesothelioma Survival Rate vs. Life Expectancy
While these terms are often used interchangeably, mesothelioma life expectancy and survival rates carry different meanings.
Life expectancy refers to the average age a person is expected to live based on the year they were born, where they were born and other demographic factors. An aggressive cancer, such as mesothelioma, can shorten this average.
Survival rates come into play after a person is diagnosed with cancer or another serious health condition. These rates show the percentage of patients in a study or treatment group who are still alive for a certain period of time following a diagnosis.
Researchers usually describe the mesothelioma survival rate in terms of one-year survival. They also measure the percentage of patients who live two years, three years and five years.
Mesothelioma has no definitive cure. Most cases are diagnosed in a late stage, after tumors have spread. This is a main reason why survival rates are generally lower compared to other cancers.
Free Mesothelioma Nutrition Guide
Eating right and balancing your diet while undergoing mesothelioma treatment can help ease your symptoms.Get Free Recipes & Tips
Factors that Affect Survival Rate
Survival rates for mesothelioma cancer vary by the patient’s age, gender, race and several other factors. The location, stage and cell type of the cancer, as well as your overall health, have the strongest influence on your mesothelioma prognosis.
Overall, older mesothelioma patients have a much lower survival rate than younger ones. More than 55 percent of patients diagnosed before the age of 50 live one year. Less than 30 percent of patients 75 or older live the same amount of time.
This difference is largely because younger patients are eligible for more intensive treatments such as surgery. Older individuals may not be candidates for these procedures because of poor overall health or a high risk of complications.
|Age Range||Survival Rate|
|50 – 64||51.2%|
|65 – 74||40.9%|
Rates are similar for long-term survival. Patients diagnosed before age 50 have nearly a 25 percent chance of surviving a decade. That drops sharply — to 5.4 percent — for patients between the ages of 50 and 64.
However, it is rare for someone younger than 50 to be diagnosed with mesothelioma. The average age at diagnosis is 69.
The five-year survival rate for patients diagnosed between ages 65-74 is 6.7 percent. That rate falls to 3.8 percent for those 75 or older.
|Gender||1 Year||2 Years||3 Years||4 Years||5 Years|
Women with mesothelioma have a nearly three-fold better survival rate compared to men. Researchers analyzed mesothelioma cases reported in the National Cancer Institute’s SEER database from 1988 to 2013. They found the overall five-year survival rate was 7 percent for men and 15 percent for women.
Most asbestos exposure occurs in the workplace. Industrial jobs traditionally held by men presented the highest risk. That helps explain why men account for the majority of all mesothelioma cases.
When asbestos use was far more pervasive decades ago, the few women who did develop a related illness were usually exposed because they lived near mines or factories that processed the mineral. Women also found themselves exposed by spouses, family members or friends who worked around asbestos and brought home the tiny fibers on their clothes.
Women with mesothelioma appear to survive longer than men regardless of age, cancer stage, race or type of treatment. For every age group studied in the SEER program, women fared significantly better than men.
There is currently no conclusive answer as to why. Some researchers believe the improved survival could be explained by hormonal differences between sexes.
Women are also more likely to be diagnosed with peritoneal mesothelioma. This type carries a better prognosis compared to the more common pleural type.
Women: The New Faces of Mesothelioma
The gender gap is closing as mesothelioma incidence rates among women are on the rise. Women now comprise nearly one-fourth of all cases.Read the Story
Mesothelioma is almost exclusive to white individuals, who make up 95 percent of patients.
This vast difference may be in large part because black and Hispanic individuals are less likely to be diagnosed with any type of cancer, mesothelioma included. Data from SEER shows blacks and Hispanics account for only 8 percent of all cancer diagnoses.
|Race||1 Year||2 Years||3 Years||4 Years||5 Years|
*Data includes Hispanics
Race does not appear to impact mesothelioma survival rate much initially. It becomes a more telling factor as time passes. From three years on, the survival rate of white patients is slightly worse than black patients.
Five-year survival among whites is 7.8 percent, compared with 12 percent for blacks. After 10 years, only 4.4 percent of white patients survive, while 8.2 percent of blacks are alive a decade after diagnosis.
SEER data used to calculate these survival rates includes Hispanics among patients who identify as both black and white. Because mesothelioma is rarer among other races, reliable survival statistics are not available.
A 2015 study analyzed 13,734 pleural mesothelioma cases in the SEER database. It found that black patients lived longer than white patients despite being less likely to undergo aggressive surgery. Only 18 percent of black patients in the study had surgery, compared to 24 percent of white patients.
Typically, mesothelioma patients who have surgery survive longer than those who do not.
Site of Mesothelioma
There are four types of mesothelioma, and the site where the cancer originates can greatly affect patient survival.
Survival is significantly better for peritoneal mesothelioma patients. This, however, has not always been the case.
The emergence of an advanced peritoneal mesothelioma therapy called hyperthermic intraperitoneal chemotherapy (HIPEC) improved survival rates. It combines cytoreductive surgery and heated chemotherapy. Not everyone qualifies for this aggressive procedure. But about half who do live at least five years.
This compares to a median survival of less than 12 months for patients with pleural mesothelioma. In select studies, heated chemotherapy has boosted peritoneal mesothelioma survival to between 40 and 92 months.
According to a 2015 meta-study analyzing 20 years of data from 1992 to 2012, the five-year survival rate for peritoneal mesothelioma patients is more than five-times higher than the rate for pleural patients.
Source: “Changing Pattern in Malignant Mesothelioma Survival,” published in the journal Translational Oncology in February 2015.
The remaining two types — pericardial and testicular mesothelioma — when combined, account for less than 2 percent of all mesothelioma cases. Median survival for testicular mesothelioma, the rarest type, is 24 months.
Pericardial mesothelioma develops on the lining of the heart. It has a median survival ranging from six to 10 months.
Stage of Mesothelioma
The stage of your mesothelioma at diagnosis is a strong predictor of overall survival. Survival is best among people diagnosed with mesothelioma at an early stage, before cancer spread starts to limit treatment options.
Early-stage patients who receive prompt treatment experience improved survival because they are more likely to qualify for surgery and other aggressive treatments associated with better outcomes.
Early-stage patients who receive prompt treatment experience improved survival. This is because they are more likely to qualify for surgery and other aggressive treatments associated with better outcomes.
Typically, pleural mesothelioma is not diagnosed until it reaches stage 3 or stage 4, the last stages of development. This can involve a larger tumor or extensive cancer spread throughout the body. Later stages of mesothelioma are more difficult to treat effectively. These patients have worse survival rates.
Talk to a Doctor About Your Diagnosis
We can help you or a loved one get a diagnosis or a second opinion from a mesothelioma specialist.Get Started Today
There is no established staging system for peritoneal mesothelioma. Some researchers have proposed their own systems based on the TNM system. TNM uses tumor size, lymph node involvement and cancer spread to describe the extent of many types of cancer.
One such novel staging system has three stages based on TNM characteristics and a measure of tumor burden. It is called the peritoneal cancer index (PCI). In a 2011 international study involving 294 peritoneal mesothelioma patients treated with cytoreductive surgery and heated chemotherapy, researchers used this system to describe patient survival.
One-year survival for stage 1 patients was 94 percent, 87 percent for stage 2 and 66 percent for stage 3. The researchers also calculated five-year survival, which was 87 percent for stage 1, 53 percent for stage 2 and 29 percent for stage 3.
|Stage 1||Stage 2||Stage 3||Stage 4|
|22.2 months||20 months||17.9 months||14.9 months|
Source: “The IASLC Mesothelioma Staging Project,” published in the Journal of Thoracic Oncology in December 2016.
The histology, or cellular makeup, of a mesothelioma tumor is also an accurate predictor for patient survival. Mesothelioma has three primary cell types: Epithelial, sarcomatoid and biphasic. They differ not only in appearance, but also in behavior.
With a median survival of 12 to 24 months, epithelioid mesothelioma — the most common cell type — has the best prognosis. Epithelioid cells are the least aggressive and respond best to treatment.
Sarcomatoid mesothelioma, on the other hand, has a median survival of six months. Sarcomatoid tumors exhibit more aggressive behavior in terms of cell growth and invasive spread. Biphasic mesothelioma has both epithelioid and sarcomatoid features. It has a median survival of 12 months.
|Cell Type||Median Surival|
A large, multi-institutional study investigated how tumor histology and other factors affect survival. The epithelioid cell type had the best survival rate, with a median survival of 19 months. Sarcomatoid patients experienced a median survival of eight months, the worst outcome of all cell types. Median survival for biphasic patients was 13 months.
Share this article
Last Modified September 28, 2018
15 Cited Article Sources
Shavelle, R., Vevra-Musser, K., Lee, J. & Brooks, J. (2017, January 23). Life Expectancy in Pleural and Peritoneal Mesothelioma. :
Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292397/
Taioli, E. et al. (2015, April 30). Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma. :
Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430630/
Surveillance, Epidemiology, and End Results Program. (n.d.). Table 17.5. Mesothelioma Survival Rates by Year of Diagnosis. All Races, Males and Females. :
Retrieved from: https://seer.cancer.gov/archive/csr/1975_2006/results_merged/sect_17_mesothelioma.pdf
Surveillance, Epidemiology, and End Results Program. (2017, May 18). Mesothelioma 5-Year Relative Survival Rates, 2007-2013 by Sex. :
Retrieved from: https://seer.cancer.gov/explorer/application.php?site=111&data_type=4&stat_type=5&compareBy=sex&series=9&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&chk_race_1=1&chk_race_3=3&chk_race_2=2&chk_age_range_1=1&chk_stage_101=101&advopt_precision=1&showDataFor=race_1_and_age_range_1_and_stage_101
Centers for Disease Control and Prevention (2009). Malignant Mesothelioma Mortality: United States, 1999-2005. :
Retrieved from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5815a3.htm
Flores, R.M. et al. (2010). Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER]) Population. Journal of Thoracic Oncology, 5(10), 1649-1654. : #
Retrieved from: http://journals.lww.com/jto/Fulltext/2010/10000/Frequency_of_Use_and_Predictors_of_Cancer_Directed.25.aspx
Leite, K.R.M., Nahas, W.C., &Camara-Lopes, L.H. (2002).Malignant Mesothelioma of the Tunica Vaginalis.Brazilian Journal of Urology, 28(2), 135-137. :
Retrieved from: http://www.brazjurol.com.br/march_april_2002/Leite_135_137.pdf
National Cancer Institute. NCI Dictionary of Cancer Terms. :
Retrieved from: http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=44301
National Institute for Occupational Safety and Health (2007).Work-Related Lung Disease Surveillance Report. :
Retrieved from: http://www.cdc.gov/niosh/docs/2008-143/pdfs/2008-143.pdf
Nilsson, A. &Rasmuson, T. (2009). Primary Pericardial Mesothelioma: Report of a Patient and Literature Review. Case Reports in Oncology, 2(2), 125-132. :
Retrieved from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918860/?tool=pubmed
Rusch, V.W. &Venkatramen, E. (1996).The Importance of Surgical Staging in the Treatment of Malignant Pleural Mesothelioma.Journal of Thoracic Cardiovascular Surgery, 111, 815-826. :
Retrieved from: http://www.jtcvsonline.org/home
Surveillance, Epidemiology, and End Results (2011).Cancer Mortality Rates. :
Retrieved from: http://www.seer.cancer.gov/statistics/types/mortality.html
Surveillance, Epidemiology, and End Results.Fast Stats. :
Retrieved from: http://seer.cancer.gov/faststats/selections.php?series=cancer
Young, J.L., Ward, K.C., &GloecklerRies, L.A. (2008).Cancers of Rare Sites. :
Retrieved from: http://seer.cancer.gov/publications/survival/surv_rare_cancers.pdf
- Nowak, A.K. et al. (2016). The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. Journal of Thoracic Oncology, 11(12), 2089-2099. doi: 10.1016/j.jtho.2016.08.147